Linzhi Han

808 total citations · 1 hit paper
21 papers, 527 citations indexed

About

Linzhi Han is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Linzhi Han has authored 21 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 7 papers in Immunology. Recurrent topics in Linzhi Han's work include RNA modifications and cancer (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and interferon and immune responses (4 papers). Linzhi Han is often cited by papers focused on RNA modifications and cancer (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and interferon and immune responses (4 papers). Linzhi Han collaborates with scholars based in China and United Kingdom. Linzhi Han's co-authors include Yan Gong, Conghua Xie, Zhengrong Huang, Jingyi He, Xueping Jiang, Yanping Gao, Wenjie Sun, Hongjie Shi, Nannan Zhang and Shuying Li and has published in prestigious journals such as PLoS ONE, Scientific Reports and Cancer Letters.

In The Last Decade

Linzhi Han

19 papers receiving 521 citations

Hit Papers

Mechanisms and management of 3rd‑generation EGFR‑TKI resi... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
    2021 193 citations Jingyi He, Zhengrong Huang et al. International Journal of Oncology profile →

Peers

Linzhi Han
Yinxing Zhu China
Lingxiong Wang China
Alessandra Bulotta Italy
Ananthan Sadagopan United States
Zuan-Fu Lim United States
Teresa Puértolas Spain
Zhaozhen Wu China
Austin J. Combest United States
Shuiling Jin China
Konrad Klinghammer Germany
Yinxing Zhu China
Linzhi Han
Citations per year, relative to Linzhi Han Linzhi Han (= 1×) peers Yinxing Zhu

Countries citing papers authored by Linzhi Han

Since Specialization
Citations

This map shows the geographic impact of Linzhi Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linzhi Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linzhi Han more than expected).

Fields of papers citing papers by Linzhi Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linzhi Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linzhi Han. The network helps show where Linzhi Han may publish in the future.

Co-authorship network of co-authors of Linzhi Han

This figure shows the co-authorship network connecting the top 25 collaborators of Linzhi Han. A scholar is included among the top collaborators of Linzhi Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linzhi Han. Linzhi Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Han, Linzhi, Ji Qian, Xiuli Guo, et al.. (2025). Radiotherapy in combination with PD-1 and TIGIT blockade mediate antitumor abscopal effects and immune memory via CD8+ T cells. Cancer Letters. 631. 217935–217935. 1 indexed citations
2.
Yang, Ran, Huijuan Wu, Xinyu Liu, et al.. (2025). Cisplatin-encapsulated zeolitic imidazolate framework-8 nanosystem enhanced radiosensitivity of non-small cell lung cancer. Scientific Reports. 15(1). 42758–42758.
3.
Gong, Yan, Tao Gan, Jian‐Guo Zhang, et al.. (2024). Targeting the LMP1‐ALIX axis in EBV + nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti‐tumor immunity. Cancer Communications. 44(12). 1391–1413. 4 indexed citations
4.
5.
Qu, Meihua, Yanhua Xu, Wenjie Sun, et al.. (2023). hsa-miR-1301-3p Promotes the Proliferation and Migration of Nonsmall Cell Lung Cancer Cells and Reduces Radiosensitivity via Targeting Homeodomain-Only Protein Homeobox. Genetic Testing and Molecular Biomarkers. 27(12). 393–405.
6.
7.
Han, Linzhi, Hongjie Shi, Shijing Ma, et al.. (2022). Agrin Promotes Non-Small Cell Lung Cancer Progression and Stimulates Regulatory T Cells via Increasing IL-6 Secretion Through PI3K/AKT Pathway. Frontiers in Oncology. 11. 804418–804418. 21 indexed citations
8.
Zeng, Zihang, Jianguo Zhang, Jiali Li, et al.. (2022). SETD2 regulates gene transcription patterns and is associated with radiosensitivity in lung adenocarcinoma. Frontiers in Genetics. 13. 935601–935601. 11 indexed citations
9.
Zeng, Zihang, Yanping Gao, Jiali Li, et al.. (2022). SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma. Genes & Diseases. 10(2). 336–339. 1 indexed citations
10.
Bai, Rui, Jianguo Zhang, Yangyi Li, et al.. (2022). GPR87 promotes tumor cell invasion and mediates the immunogenomic landscape of lung adenocarcinoma. Communications Biology. 5(1). 663–663. 9 indexed citations
11.
Zhang, Nannan, Yanping Gao, Panpan Dai, et al.. (2022). PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy. Cancer Letters. 545. 215852–215852. 40 indexed citations
12.
13.
Sun, Wenjie, Shuying Li, Guiliang Tang, et al.. (2021). HHLA2 deficiency inhibits non‐small cell lung cancer progression and THP‐1 macrophage M2 polarization. Cancer Medicine. 10(15). 5256–5269. 36 indexed citations
14.
Luo, Yuan, Shijing Ma, Yingming Sun, et al.. (2021). MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer. International Journal of Biological Sciences. 17(7). 1671–1681. 14 indexed citations
15.
Jiang, Xueping, Yangyi Li, Nannan Zhang, et al.. (2021). RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma. Cell & Bioscience. 11(1). 74–74. 45 indexed citations
16.
Li, Shuying, Wenjie Sun, Yuan Luo, et al.. (2021). Hollow PtCo alloy nanospheres as a high-Z and oxygen generating nanozyme for radiotherapy enhancement in non-small cell lung cancer. Journal of Materials Chemistry B. 9(23). 4643–4653. 34 indexed citations
17.
He, Jingyi, Zhengrong Huang, Linzhi Han, Yan Gong, & Conghua Xie. (2021). Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review). International Journal of Oncology. 59(5). 193 indexed citations breakdown →
18.
Luo, Yuan, Yuan Cheng, Linzhi Han, et al.. (2020). Downregulation of Nitric Oxide Collaborated with Radiotherapy to Promote Anti-Tumor Immune Response via Inducing CD8+ T Cell Infiltration. International Journal of Biological Sciences. 16(9). 1563–1574. 21 indexed citations
19.
Shi, Hongjie, Jinping Zhao, Linzhi Han, et al.. (2020). Retrospective study of gene signatures and prognostic value of m6A regulatory factor in non-small cell lung cancer using TCGA database and the verification of FTO. Aging. 12(17). 17022–17037. 31 indexed citations
20.
Han, Linzhi, Hongjie Shi, Yuan Luo, et al.. (2020). Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma. Cancer Medicine. 9(24). 9581–9594. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yinxing Zhu Breakdown of academic impact, for papers by Lingxiong Wang Breakdown of academic impact, for papers by Alessandra Bulotta Breakdown of academic impact, for papers by Ananthan Sadagopan Breakdown of academic impact, for papers by Zuan-Fu Lim Breakdown of academic impact, for papers by Teresa Puértolas Breakdown of academic impact, for papers by Zhaozhen Wu Breakdown of academic impact, for papers by Austin J. Combest Breakdown of academic impact, for papers by Shuiling Jin Breakdown of academic impact, for papers by Konrad Klinghammer
Rankless by CCL
2026